This latest research on non-dystrophic myotonia offers promising results for those affected by the condition. Published in Lancet Neurology00320-X/fulltext), the study details a “head-to-head” trial comparing two drugs—mexiletine and lamotrigine—to find effective treatments for this rare muscle disorder. The results highlight potential improvements in managing the debilitating symptoms of this condition and provide an expanded range of treatment options. The trial took place at the UCL Queen Square Multidisciplinary Centre for Neuromuscular Diseases and the National Hospital for Neurology and …